Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 32, 2023 - Issue 11
Submit an article Journal homepage
772
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials

Sylvia BoeschCenter for Rare Movement Disorders Innsbruck, Department of Neurology, Medical University of Innsbruck, Innsbruck, AustriaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1657-7368View further author information
ORCID Icon &
Elisabetta IndelicatoCenter for Rare Movement Disorders Innsbruck, Department of Neurology, Medical University of Innsbruck, Innsbruck, AustriaORCID Iconhttps://orcid.org/0000-0003-0217-8630View further author information
ORCID Icon
Pages 967-969 | Received 21 Sep 2023, Accepted 25 Oct 2023, Published online: 30 Oct 2023

References

  • Indelicato E, Nachbauer W, Eigentler A, et al. Onset features and time to diagnosis in Friedreich’s Ataxia. Orphanet J Rare Dis. 2020;15(1). doi: 10.1186/s13023-020-01475-9
  • Campuzano V, Montermini L, Moltò MD, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;80-) 271(5254):1423–1427. doi: 10.1126/science.271.5254.1423
  • Reetz K, Dogan I, Hilgers RD, et al. Progression characteristics of the European Friedreich’s Ataxia consortium for translational studies (EFACTS): a 2 year cohort study. Lancet Neurol. 2016;15(13):1346–1354. doi: 10.1016/S1474-4422(16)30287-3
  • Rummey C, Corben LA, Delatycki M, et al. Natural history of Friedreich Ataxia: heterogeneity of neurologic progression and consequences for clinical trial design. Neurology. 2022;99(14):E1499–E1510. doi: 10.1212/WNL.0000000000200913
  • Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich Ataxia. J Neurol Sci. 2011;307(1–2):46–49. doi: 10.1016/j.jns.2011.05.023
  • Indelicato E, Bösch S. Emerging therapeutics for the treatment of Friedreich’s ataxia. Expert Opin Orphan Drugs. 2018;6(1):57–67. doi: 10.1080/21678707.2018.1409109
  • Rodden LN, Lynch DR. Designing phase II clinical trials in Friedreich ataxia. Expert Opin Emerg Drugs. 2021;26(4):415–423. doi: 10.1080/14728214.2021.1998452
  • Lee A. Omaveloxolone: First Approval. Drugs. 2023;83(8):725–729. doi: 10.1007/s40265-023-01874-9
  • Paupe V, Dassa EP, Goncalves S, et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich Ataxia. PLoS One. 2009;4(1):e4253. doi: 10.1371/JOURNAL.PONE.0004253
  • Lynch DR, Chin MP, Delatycki MB, et al. Safety and Efficacy of omaveloxolone in Friedreich Ataxia (MOXIe study). Ann Neurol. 2021;89(2):212–225. doi: 10.1002/ANA.25934
  • Lynch DR, Chin MP, Boesch S, et al. Efficacy of omaveloxolone in Friedreich’s Ataxia: delayed-start analysis of the MOXIe extension. Mov Disord. 2023;38(2):313–320. doi: 10.1002/MDS.29286
  • Patel M, Isaacs CJ, Seyer L, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol. 2016;3(9):684–694. doi: 10.1002/ACN3.332
  • Weber SC. The evolution and use of patient-reported outcomes in regulatory decision making. Regul Focus Q. 2023;3:4–9.
  • Pandolfo M, Reetz K, Darling A, et al. Efficacy and safety of Leriglitazone in patients with Friedreich Ataxia: a phase 2 double-blind, randomized controlled trial (FRAMES). Neurol Genet. 2022;8(6):e200034. doi: 10.1212/NXG.0000000000200034
  • Sivakumar A, Cherqui S. Advantages and limitations of gene therapy and gene editing for Friedreich’s Ataxia. Front Genome Ed. 2022;4:903139. doi: 10.3389/fgeed.2022.903139
  • Babcock M, De Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997;80-) 276(5319):1709–1712. doi: 10.1126/science.276.5319.1709
  • Pandolfo M, Arpa J, Delatycki MB, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014;76(4):509–521. doi: 10.1002/ana.24248
  • 2023Hyperkinetic Movement DisordersMov DisordVol. 3810.1002/MDS.29542
  • Indelicato E, Kirchmair A, Amprosi M, et al. Skeletal muscle transcriptomics dissects the pathogenesis of Friedreich’s ataxia. Hum Mol Genet. 2023;32(13):2241–2250. doi: 10.1093/HMG/DDAD051
  • C-Path and FARA Launch Friedreich’s Ataxia integrated clinical database to advance the development of treatments for FA. [cited 2019 Feb 27]. https://c-path.org/c-path-and-fara-launch-friedreichs-ataxia-integrated-clinical-database-to-advance-the-development-of-treatments-for-fa/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.